Amphastar PharmaceuticalsAMPH -0.42%83 3-Year ROIIC % is 3.56 as of Dec. 2025, which is 68% below its 10-year median of 11.05. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.79 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 943 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks worse than 50.37% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Amphastar Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 3.56%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Amphastar Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
AMPH's 3-Year ROIIC % is ranked worse than 50.37% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs AMPH: 3.56
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Amphastar Pharmaceuticals 3-Year ROIIC % Related Terms
Amphastar Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMPH vs ETON, PCRX, BIOA: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Amphastar Pharmaceuticals (AMPH) has a 3-Year ROIIC % of 3.56 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Amphastar Pharmaceuticals and its competitors. This is 68% below median its historical median of 11.05. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #475 out of 943 companies in the Drug Manufacturers industry, placing it in the top 50.4%.
Is Amphastar Pharmaceuticals' 3-Year ROIIC % too high?
Amphastar Pharmaceuticals' current 3-Year ROIIC % of 3.56 is 68% below median its 10-year median of 11.05. The Drug Manufacturers industry median 3-Year ROIIC % is 3.74. Amphastar Pharmaceuticals' value of 3.56 is 4.8% below this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #475 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' 3-Year ROIIC % compare to ETON and PCRX?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #475 out of 943 companies for 3-Year ROIIC %. This places Amphastar Pharmaceuticals in the lower half of its industry. The industry median 3-Year ROIIC % is 3.74. Amphastar Pharmaceuticals' value of 3.56 is 4.8% below this benchmark. While the company's 10-year median is 11.05 vs. the industry median of 3.74, Amphastar Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current 3-Year ROIIC % of 3.56 is 4.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current 3-Year ROIIC % is 3.56, which is 68% below median its own 10-year median of 11.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.79, compared to a current price of $20.02 — trading 59% below its estimated fair value. The current 3-Year ROIIC % is 3.56, which is 68% below median its 10-year median of 11.05 and 4.8% below the Drug Manufacturers industry median of 3.74. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current 3-Year ROIIC % is 3.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.02 is trading 59% below its estimated GF Value™ of $48.79.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
3-Year ROIIC %: 3.56 (68% below median its 10-year median of 11.05)
GF Value™: $48.79 vs. price of $20.02 (59% below fair value)
Industry Position: 4.8% below the Drug Manufacturers median (#475 of 943)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
